AUNA S.A. Reports Adverse Opinion on Internal Controls, Declining Profitability in 2025 Annual Report

summarizeSummary

AUNA S.A.'s 2025 annual report discloses an adverse opinion from its auditor on internal control over financial reporting, alongside a 10.5% decrease in profit and a 7.6% drop in Adjusted EBITDA, despite successful debt refinancing activities.

check_boxKey Events

• Adverse Opinion on Internal Controls

  The independent auditor issued an adverse opinion on the effectiveness of internal control over financial reporting as of December 31, 2025, citing material weaknesses in IT general controls and process-level controls.

• Declining Profitability

  Profit for the year decreased by 10.5% to S/110.9 million, and Adjusted EBITDA fell by 7.6% to S/916.5 million in 2025 compared to 2024.

• Significant Debt Refinancing

  The company issued US$365 million Senior Secured Notes due 2032 and secured US$460 million in term loans, using the proceeds to repurchase US$274.3 million of 2029 Notes and prepay other debt.

• PPP Agreement Progress

  A second amendment to the Centro Ambulatorio Trecca Public-Private Partnership Agreement was signed in February 2026, updating economic conditions and paving the way for the investment phase to begin in 2026.

auto_awesomeAnalysis

AUNA S.A.'s 2025 annual report reveals a critical issue with an adverse opinion from its auditor on the effectiveness of internal control over financial reporting. This indicates fundamental deficiencies in the company's financial reporting processes, which can significantly erode investor confidence and raises questions about the reliability of financial data. Concurrently, the company reported a 10.5% decrease in profit and a 7.6% drop in Adjusted EBITDA for 2025, highlighting operational challenges, particularly a 13% revenue decline in its Mexico segment. While AUNA S.A. successfully refinanced a substantial portion of its debt by issuing US$365 million Senior Secured Notes due 2032 and securing US$460 million in term loans, using proceeds to repurchase US$274.3 million of 2029 Notes and prepay other obligations, the underlying operational performance and control weaknesses are key areas for investor scrutiny. The update on the long-delayed Centro Ambulatorio Trecca PPP project is a positive development for future growth, but its financial impact is not immediate. Investors should closely monitor the company's remediation efforts for internal controls and the performance of its key segments.